236 
Market Cap
Stock Chart
Novogen - 30 Day Poll
Recent BLOGS About Novogen Add New
Latest Company News
|
NOVOGEN LIMITED : Marshall Edwards completes rights offering to stockholders
4-traders - May 14, 2012 San Diego - 14 May, 2012 -Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the completion of its previously announced rights offering to ...
|
|
Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
PR Newswire (press release) - May 8, 2012 SYDNEY, May 8, 2012 /PRNewswire/ -- Novogen Limited (ASX: NRT Nasdaq: NVGN), announced today that following approval by its shareholders at an Extraordinary General Meeting held on 7 May, 2012, its Board of Directors has resolved to make a US$4 million ...
|
|
Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
MarketWatch (press release) - May 8, 2012 SYDNEY, May 8, 2012 /PRNewswire via COMTEX/ -- Novogen Limited (asx:NRT Nasdaq), announced today that following approval by its shareholders at an Extraordinary General Meeting held on 7 May, 2012, its Board of Directors has resolved to make a US$4 ...
Giving you all the latest in Stock Market Information as it happens... - egoli.com.au |
|
Marshall Edwards, Inc. Receives $4 Million Subscription From Novogen Ltd In Rights Offering
Reuters Key Development - May 8, 2012 |
|
Novogen Limited's Marshall Edwards, Inc. Announces Issuance Of New Method Of Use Patent By The US Patent and Trademark Office
Reuters Key Development - Jan 3, 2012 |
Website
Videos related to Novogen
Company Profile
Cash on hand: A$32.3 million as of 30th June 2009
Novogen is based on a family of naturally-occurring plant compounds known as flavonoids which are important and primitive regulators of such basic functions of cells in Nature as how they survive and maintain normal vigor and then die at a predetermined time. Such effects occur also in human cells and humans consume flavonoids in such substantial quantities.
The company has Phase I, Phase II & Phase III (for cervical cancer) compounds. General areas of focus include:
- Cancer
- Heart disease (stroke, hypertension, coronary artery disease)
- Osteoporosis
- Chronic inflamatory diseases (rheumatoid arthritis, osteoarthritis, chronic back pain)
- Inflammatory Bowel Disease (ulcerative colitis, Crohn's Disease)
Novogen is addressing this area of medical need through the Novogen isoflavonoid technology platform - a platform that the Company believes offers the prospect of not only treating, but also preventing, the onset of these common degenerative conditions. And includes at l;east 2 divisions:
1. Pharmaceutical division – developing an extensive portfolio of prescription drugs
2. Consumer health division – developing a range of non-prescription products meeting important health needs of men and women